Generation and characterization of monoclonal antibodies against a cyclic variant of hepatitis C virus E2 epitope 412-422

Journal of Virology

Volumn 90, Issue 7, 2016, Pages 3745-3759

  Sandomenico, Annamaria ^a   Leonardi, Antonio ^a   Berisio, Rita ^a   Sanguigno, Luca ^a,e   Focà, Giuseppina ^a,f   Focà, Annalia ^a,f   Ruggiero, Alessia ^a   Doti, Nunzianna ^a   Muscariello, Livio ^b   Barone, Daniela ^a,c   Farina, Claudio ^b   Owsianka, Ania ^d   Vitagliano, Luigi ^a   Patel, Arvind H ^d   Ruvo, Menotti ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Kedrion SpA Loc Ai Conti   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e Bioker Multimedica   (Italy)

^f CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; E2 PROTEIN; EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; EPITOPE MAPPING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE EVASION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HEPACIVIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR MODEL; PROTEIN CONFORMATION; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; EPITOPES, B-LYMPHOCYTE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; MICE, INBRED BALB C; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN CONFORMATION; VIRAL ENVELOPE PROTEINS;

EID: 84960970619     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02397-15     Document Type: Article

References (52)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx.doi.org/10.1002/hep.26141.
2. Galossi A, Guarisco R, Bellis L, Puoti C. 2007. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 16:65-73.
3. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. http://dx.doi.org/10.1002/hep.20819.
4. Smith DB, Bukh J, Kuiken C, MuerhoffAS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
5. Belousova V, Abd-Rabou AA, Mousa SA. 2015. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 145:92-102. http://dx.doi.org/10.1016/j.pharmthera.2014.09.002.
6. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZY, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. 2014. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756-1765. http://dx.doi.org/10.1016/S0140-6736(14)61036-9.
7. Koretz RL. 2014. ACP journal club: review: telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1. Ann Intern Med 161:JC11. http://dx.doi.org/10.7326/0003-4819-161-10-201411180-02011.
8. Lindenbach BD, MC Rice. 2013. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11:688-700. http://dx.doi.org/10.1038/nrmicro3098.
9. Goffard A, Dubuisson J. 2003. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85:295-301. http://dx.doi.org/10.1016/S0300-9084(03)00004-X.
10. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941. http://dx.doi.org/10.1126/science.282.5390.938.
11. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017-5025. http://dx.doi.org/10.1093/emboj/cdf529.
12. Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80:8695-8704. http://dx.doi.org/10.1128/JVI.00271-06.
13. Drummer HE, Boo I, Maerz AL, Poumbourios P. 2006. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 80: 7844-7853. http://dx.doi.org/10.1128/JVI.00029-06.
14. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79:11095-11104. http://dx.doi.org/10.1128/JVI.79.17.11095-11104.2005.
15. Flint M, Maidens CM, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73:6235-6244.
16. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD, Jr, Szabo G, Finberg RW, Ambrosino DM, Babcock GJ. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83:12473-12482. http://dx.doi.org/10.1128/JVI.01138-09.
17. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK. 2013. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 87:37-51. http://dx.doi.org/10.1128/JVI.01941-12.
18. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, Takeda K, Date S, Cheung TK, Phung Q, Hass P, Arnott D, Hongo JA, Matthews DJ, Brown A, Patel AH, Kelley RF, Eigenbrot C, Kapadia SB. 2013. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425:1899-1914. http://dx.doi.org/10.1016/j.jmb.2013.02.025.
19. Kong L, Jackson KN, Wilson I, Law M. 2015. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 11:148-157. http://dx.doi.org/10.1016/j.coviro.2015.04.001.
20. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, Virata-Theimer ML, Alter HJ, Feinstone S, Major M. 2009. Depletion of interfering antibodies in chronic hepatitisCpatients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106:7537-7541. http://dx.doi.org/10.1073/pnas.0902749106.
21. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8:e1002653. http://dx.doi.org/10.1371/journal.ppat.1002653.
22. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104: 16269-16274. http://dx.doi.org/10.1073/pnas.0705522104.
23. Ball JK, Tarr AW, McKeating JA. 2014. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 105:100-111. http://dx.doi.org/10.1016/j.antiviral.2014.02.013.
24. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH. 2012. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 86:12923-12932. http://dx.doi.org/10.1128/JVI.02052-12.
25. Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL, Wilson IA, Law M. 2012. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol 86:13085-13088. http://dx.doi.org/10.1128/JVI.01939-12.
26. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109:9499-9504. http://dx.doi.org/10.1073/pnas.1202924109.
27. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J. 2014. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509:381-384. http://dx.doi.org/10.1038/nature13117.
28. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. 2013. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342:1090-1094. http://dx.doi.org/10.1126/science.1243876.
29. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601. http://dx.doi.org/10.1002/hep.21088.
30. Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH. 2002. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76:7672-7682. http://dx.doi.org/10.1128/JVI.76.15.7672-7682.2002.
31. Fields GB, Noble RL. 1990. Solid phase peptide synthesis utilizing 9 fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214.
32. Verdoliva A, Marasco D, De Capua A, Saporito A, Bellofiore P, Manfredi V, Fattorusso R, Pedone C, Ruvo M. 2005. A new ligand for immunoglobulin G subdomains by screening of a synthetic peptide library. Chembiochem 6:1242-1253. http://dx.doi.org/10.1002/cbic.200400368.
33. Saporito A, Marasco D, Chambery A, Botti P, Monti SM, Pedone C, Ruvo M. 2006. The chemical synthesis of the GstI protein by NCL on a X-Met site. Biopolymers 83:508-518. http://dx.doi.org/10.1002/bip.20582.
34. Carter JM. 1994. Techniques for conjugation of synthetic peptides to carrier molecules. Methods Mol Biol 36:155-191.
35. Kohler G, Milstein C. 1976. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6:511-519. http://dx.doi.org/10.1002/eji.1830060713.
36. Focà A, Sanguigno L, Focà G, Strizzi L, Iannitti R, Palumbo R, Hendrix MJC, Leonardi A, Ruvo M, Sandomenico A. 2015. New anti-nodal monoclonal antibodies targeting the nodal pre-helix loop involved in Cripto-1 binding. Int J Mol Sci 16:21342-21362. http://dx.doi.org/10.3390/ijms160921342.
37. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. 2000. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 81:2873-2883. http://dx.doi.org/10.1099/0022-1317-81-12-2873.
38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. http://dx.doi.org/10.1038/nm1268.
39. Keck Z-Y, Angus AGN, Wang W, Lau L, Wang Y, Gatherer D, Patel A, Foung SKH. 2014. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog 10:e1004297. http://dx.doi.org/10.1371/journal.ppat.1004297.
40. Iro M, Witteveldt J, Angus AG, Woerz I, Kaul A, Bartenschlager R, Patel AH. 2009. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res 83:148-155. http://dx.doi.org/10.1016/j.antiviral.2009.04.007.
41. Jankarik J, Kim S. 1991. Sparse matrix sampling: a screening method for crystallization of proteins. J Appl Crystallogr 24:409-411. http://dx.doi.org/10.1107/S0021889891004430.
42. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X.
43. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40: 658-674. http://dx.doi.org/10.1107/S0021889807021206.
44. Morris RJ, Perrakis A, Lamzin VS. 2002. ARP/wARP's model-building algorithms. I. The main chain. Acta CrystallogrDBiol Crystallogr 58:968-975. http://dx.doi.org/10.1107/S0907444902005462.
45. Winn MD, Murshudov GN, Papiz MZ. 2003. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 374: 300-321. http://dx.doi.org/10.1016/S0076-6879(03)74014-2.
46. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158.
47. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. 2005. GROMACS: fast, flexible, and free. J Comput Chem 26:1701-1718. http://dx.doi.org/10.1002/jcc.20291.
48. Stanfield RL, Zemla A, Wilson IA, Rupp B. 2006. Antibody elbow angles are influenced by their light chain class. J Mol Biol 357:1566-1574. http://dx.doi.org/10.1016/j.jmb.2006.01.023.
49. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, SheriffS, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzar PM, Poljak RJ. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-883. http://dx.doi.org/10.1038/342877a0.
50. Shen Y, Maupetit J, Derreumaux P, Tufféry P. 2014. Improved PEPFOLD approach for peptide and miniprotein structure prediction. J Chem Theor Comput 10:4745-4758. http://dx.doi.org/10.1021/ct500592m.
51. Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA. 2015. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 290:10117-10125. http://dx.doi.org/10.1074/jbc. M115.643528.
52. Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T. 2015. Structural flexibility of a conserved broadly neutralizing epitope in hepatitis C virus glycoprotein E2. J Virol 89:2170-2181. http://dx.doi.org/10.1128/JVI.02190-14.